Oph1

OphRx Ltd. · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	Oph1
Sponsor	OphRx Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Feasibility Study to Evaluate the Tolerability of Oph1 Compared to Restasis in Healthy Volunteers (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Oph1 CI brief — competitive landscape report
Oph1 updates RSS · CI watch RSS
OphRx Ltd. portfolio CI